跳至主要内容
临床试验/CTRI/2021/07/035030
CTRI/2021/07/035030已完成未知

A STUDY TO EVALUATE UTILITY OF ORAL PALLIATIVE METRONOMICCHEMOTHERAPY REGIMEN IN PATIENTS WITH RELAPSED/REFRACTORYLYMPHOMA OR PATIENTS WITH LYMPHOMA UNFIT FOR CONVENTIONALINJECTABLE CHEMOTHERAPY: AN EXPLORATORY STUDY - LPEC

Postgraduate Institute of Medical Education and Research0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Relapsed/Refractory Lymphoma Patient.
  • 2. Patients unfit for full dose injectable chemotherapy defined as:
  • a) Patients with an active infection at the time of starting chemotherapy defined
  • by either a clinical, radiological or microbiological evidence of infection that
  • would preclude immediate use of full dose anticancer regimen.18
  • b) Patient with compromised organ function
  • i. Compromised cardiac function (LVEF <40%).
  • ii. Uncontrolled COPD with poor respiratory reserve.
  • iii. End stage liver or renal functions.
  • iv. Dementia or any neurological deficit precluding use of full dose CT.
  • 3. Patients not willing for injectable cytoreductive chemotherapy.
  • 4. Absolute neutrophil count ââ?°Â¥ 1000 cell / Ã?¼l or platelet count ââ?°Â¥ 50,000/Ã?µl, not
  • related to the primary lymphoma

排除标准

  • 1. Pregnant females
  • 2. Lactating females
  • 3. Younger than 18 years
  • 4. Patient suffering from uncontrolled Hepatitis B and Hepatitis C infection.
  • 5. Central nervous system lymphoma.

研究者

相似试验